Document And Entity Information
Document And Entity Information - shares | 9 Months Ended | |
Dec. 31, 2023 | Feb. 20, 2024 | |
Document Information Line Items | ||
Entity Registrant Name | REST EZ, INC. | |
Document Type | 10-Q | |
Current Fiscal Year End Date | --03-31 | |
Entity Common Stock, Shares Outstanding | 27,537,033 | |
Amendment Flag | false | |
Entity Central Index Key | 0001733861 | |
Entity Current Reporting Status | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Document Period End Date | Dec. 31, 2023 | |
Document Fiscal Year Focus | 2024 | |
Document Fiscal Period Focus | Q3 | |
Entity Small Business | true | |
Entity Emerging Growth Company | true | |
Entity Shell Company | false | |
Entity Ex Transition Period | false | |
Document Quarterly Report | true | |
Document Transition Report | false | |
Entity File Number | 333-256498 | |
Entity Incorporation, State or Country Code | WY | |
Entity Tax Identification Number | 82-4268982 | |
Entity Address, Address Line One | 1398 W. Mason Hollow Dr. | |
Entity Address, City or Town | Riverton | |
Entity Address, State or Province | UT | |
Entity Address, Postal Zip Code | 84065 | |
City Area Code | (801) | |
Local Phone Number | 300-2542 | |
Title of 12(b) Security | None | |
No Trading Symbol Flag | true | |
Security Exchange Name | NONE | |
Entity Interactive Data Current | Yes |
BALANCE SHEETS
BALANCE SHEETS - USD ($) | Dec. 31, 2023 | Mar. 31, 2023 |
Current assets | ||
Cash | $ 0 | $ 44 |
Inventory | 2,550 | 2,550 |
Total Current Assets | 2,550 | 2,594 |
Total Assets | 2,550 | 2,594 |
Current liabilities | ||
Accounts payable | 430 | 96 |
Income taxes payable | 41,687 | 41,687 |
Total current liabilities | 50,305 | 173,158 |
Stockholders' deficit | ||
Common stock, $0.001 par value, 100,000,000 shares authorized, 23,020,033 and 20,000 shares issued and outstanding as of December 31, 2023 and March 31, 2023, respectively | 23,020 | 20,000 |
Additional paid-in capital | 264,901 | 121,589 |
Accumulated deficit | (335,676) | (312,153) |
Total stockholders' deficit | (47,755) | (170,564) |
Total liabilities and stockholders' deficit | 2,550 | 2,594 |
Related Party [Member] | ||
Current liabilities | ||
Loan from related party | $ 8,188 | $ 131,375 |
BALANCE SHEETS (Parentheticals)
BALANCE SHEETS (Parentheticals) - $ / shares | Dec. 31, 2023 | Mar. 31, 2023 |
Statement of Financial Position [Abstract] | ||
Common stock, par value (in Dollars per share) | $ 0.001 | $ 0.001 |
Common stock, shares issued | 23,020,033 | 20,000 |
Common stock, shares outstanding | 23,020,033 | 20,000 |
Common stock, shares authorized | 100,000,000 | 100,000,000 |
STATEMENTS OF OPERATIONS
STATEMENTS OF OPERATIONS - USD ($) | 3 Months Ended | 9 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2023 | Dec. 31, 2022 | |
Income Statement [Abstract] | ||||
Revenue | $ 0 | $ 0 | $ 0 | $ 0 |
Cost of goods sold | 0 | 0 | 0 | 0 |
Gross profit | 0 | 0 | 0 | 0 |
Operating expenses: | ||||
General and administrative | 1,020 | 2,061 | 17,691 | 11,179 |
Total operating expenses | 1,020 | 2,061 | 17,691 | 11,179 |
Net operating loss | (1,020) | (2,061) | (17,691) | (11,179) |
Other expense: | ||||
Interest expense | (164) | (2,586) | (5,832) | (7,671) |
Total other expense | (164) | (2,586) | (5,832) | (7,671) |
Loss before provision for income taxes | (1,184) | (4,647) | (23,523) | (18,850) |
Provision for income taxes | 0 | 0 | 0 | 0 |
Net loss | $ (1,184) | $ (4,647) | $ (23,523) | $ (18,850) |
Net loss per share - basic (in Dollars per share) | $ 0 | $ (0.23) | $ (0.03) | $ (0.94) |
Net loss per share - diluted (in Dollars per share) | $ 0 | $ (0.23) | $ (0.03) | $ (0.94) |
Weighted average shares outstanding - basic (in Shares) | 2,270,003 | 20,000 | 772,728 | 20,000 |
Weighted average shares outstanding - diluted (in Shares) | 2,270,003 | 20,000 | 772,728 | 20,000 |
STATEMENT OF CHANGES IN STOCKHO
STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) - USD ($) | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Total |
Balance at Mar. 31, 2022 | $ 20 | $ 131,271 | $ 116,553 | $ 247,844 |
Balance (in Shares) at Mar. 31, 2022 | 20,000 | |||
Imputed interest on related party loan | 7,671 | 7,671 | ||
Net loss | (18,850) | (18,850) | ||
Balance at Dec. 31, 2022 | $ 20 | 138,942 | 97,703 | 236,665 |
Balance (in Shares) at Dec. 31, 2022 | 20,000 | |||
Balance at Sep. 30, 2022 | $ 20 | 136,356 | 102,350 | 238,726 |
Balance (in Shares) at Sep. 30, 2022 | 20,000 | |||
Imputed interest on related party loan | 2,586 | 2,586 | ||
Net loss | (4,647) | (4,647) | ||
Balance at Dec. 31, 2022 | $ 20 | 138,942 | 97,703 | 236,665 |
Balance (in Shares) at Dec. 31, 2022 | 20,000 | |||
Balance at Mar. 31, 2023 | $ 20 | 141,569 | (312,153) | $ (170,564) |
Balance (in Shares) at Mar. 31, 2023 | 20,000 | 20,000 | ||
Common stock issued for conversion of loan payable | $ 23,000 | 117,500 | $ 140,500 | |
Common stock issued for conversion of loan payable (in Shares) | 23,000,000 | |||
Common stock issued for rounding (reverse stock split) (in Shares) | 33 | 33 | ||
Imputed interest on related party loan | 5,832 | $ 5,832 | ||
Net loss | (23,523) | (23,523) | ||
Balance at Dec. 31, 2023 | $ 23,020 | 264,901 | (335,676) | $ (47,755) |
Balance (in Shares) at Dec. 31, 2023 | 23,020,033 | 23,020,033 | ||
Balance at Sep. 30, 2023 | $ 20 | 147,237 | (334,492) | $ (187,235) |
Balance (in Shares) at Sep. 30, 2023 | 20,000 | 20,000 | ||
Common stock issued for conversion of loan payable | $ 23,000 | 117,500 | $ 140,500 | |
Common stock issued for conversion of loan payable (in Shares) | 23,000,000 | |||
Common stock issued for rounding (reverse stock split) (in Shares) | 33 | |||
Imputed interest on related party loan | 164 | 164 | ||
Net loss | (1,184) | (1,184) | ||
Balance at Dec. 31, 2023 | $ 23,020 | $ 264,901 | $ (335,676) | $ (47,755) |
Balance (in Shares) at Dec. 31, 2023 | 23,020,033 | 23,020,033 |
STATEMENTS OF CASH FLOWS
STATEMENTS OF CASH FLOWS - USD ($) | 3 Months Ended | 9 Months Ended | ||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2023 | Dec. 31, 2022 | |
CASH FLOWS FROM OPERATING ACTIVITIES | ||||
Net loss | $ (1,184) | $ (4,647) | $ (23,523) | $ (18,850) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||||
Imputed interest on related party loan | 164 | 2,586 | 5,832 | 7,671 |
Changes in assets and liabilities: | ||||
Accounts payable | 334 | 96 | ||
Net cash used in operating activities | (17,357) | (11,083) | ||
CASH FLOWS FROM FINANCING ACTIVITIES | ||||
Proceeds from related party debt | 473 | 17,313 | 10,829 | |
Net cash provided by financing activities | 17,313 | 10,829 | ||
Net decrease in cash and cash equivalents | (44) | (254) | ||
Cash and cash equivalents at beginning of period | 44 | 431 | ||
Cash and cash equivalents at end of period | $ 0 | $ 177 | 0 | 177 |
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: | ||||
Interest paid | 0 | 0 | ||
Income taxes paid | 0 | 0 | ||
NON-CASH INVESTING AND FINANCING ACTIVITIES: | ||||
Conversion of loan payable to common stock | $ 140,500 | $ 0 |
General Organization and Busine
General Organization and Business | 9 Months Ended |
Dec. 31, 2023 | |
Accounting Policies [Abstract] | |
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] | Note 1. General Organization and Business Rest EZ, Inc. (the “Company”) was incorporated on October 17, 2016. The Company has passed through all stages of development to full operations from incorporation, at the present time the company is currently in full Production and Distribution to wholesalers and retailers as well as online at www.RestEz.net. Rest EZ Inc. has commenced its major operations of having one product a liquid gel capsule named Rest EZ Sleep Aid Supplement, manufactured by an unaffiliated outside provider (Sport Energy) that manufactures liquid gels to various Companies, but has not distributed this product to anyone except Rest EZ Inc. The Company’s year-end is March 31. |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 9 Months Ended |
Dec. 31, 2023 | |
Accounting Policies [Abstract] | |
Significant Accounting Policies [Text Block] | Note 2. Summary of Significant Accounting Policies Basis of Presentation The financial statements have been prepared in accordance with United States generally accepted accounting principles and reflect all adjustments which, in the opinion of management, are necessary for a fair presentation. All such adjustments are of a normal recurring nature. Interim results are not necessarily indicative of results for a full year. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the Company’s financial statements for the year ended March 31, 2023, contained in the Company’s annual report on 10-K/A filed with the SEC on September 13, 2023. On September 26, 2023, the Company’s board of directors approved a reverse stock split in the ration of 1 for 1000. There were 20,000,000 shares of the Company’s common stock outstanding immediately before the reverse stock split, and 20,000 shares of common stock outstanding immediately after the reverse stock split, a decrease of 19,980,000 shares. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, revenue and expenses, and disclosure of contingent liabilities in advance of all conditions being met at the date of the financial statements. Actual results could differ from those estimates. Fair Value of Financial Instruments The Company’s balance sheet includes certain financial instruments. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period between the origination of these instruments and their expected realization. FASB Accounting Standards Codification (ASC) 820 Fair Value Measurements and Disclosures Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means. Level 3 - Inputs that are both significant to the fair value measurement and unobservable. The adoption of this standard did not have a material effect on the Company’s financial statements as reflected herein. The carrying amounts of cash and accrued expenses reported on the balance sheet are estimated by management to approximate fair value primarily due to the short-term nature of the instruments. The Company had no items that required fair value measurement on a recurring basis. Revenue Recognition The Company recognizes revenue from product sales upon product delivery. All of our products are shipped through a third-party fulfillment center to the customer and the customer takes title to product and assumes risk and ownership of the product when it is delivered. Shipping charges to customers and sales taxes collectible from customers, if any, are included in revenues. Deferred revenue recorded on the balance sheet represents payments received by the Company in advance of the product being delivered. We adopted ASC Topic 606, “Revenue from Contracts with Customers”, and all related interpretations for recognition of our revenue. Under ASC 606, the Company recognizes revenue from the commercial sales of products by applying the following steps: (1) identifying the contract with a customer; (2) identifying the performance obligations in the contract; (3) determining the transaction price; (4) allocating the transaction price to each performance obligation in the contract; and (5) recognizing revenue when each performance obligation is satisfied. Cash and Cash Equivalents All cash is maintained with a major financial institution in the United States. Deposits with this bank may occasionally exceed the amount of insurance provided on such deposits. For the purpose of the financial statements, cash includes cash in banks. Cash was $0 and $44 as of December 31, 2023 and March 31, 2023, respectively. There were no cash equivalents as of December 31, 2023 and March 31, 2023. The Federal Deposit Insurance Corporation (“FDIC”) insures these balances up to $250,000. Inventories Inventories are stated at the lower of cost or net realizable value, using the first-in, first-out method. The Company reviews its inventory for obsolescence and any inventory identified as obsolete is reserved or written off. The Company’s determination of obsolescence is based on assumptions about the demand for its products, product expiration dates, estimated future sales, and management’s future plans. Income Taxes The Company accounts for income taxes under ASC 740 Income Taxes Commitments and Contingencies The Company follows subtopic 450-20 of the FASB Accounting Standards Codification to report accounting for contingencies. Certain conditions may exist as of the date the financial statements are issued, which may result in a loss to the Company, but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. There are no known commitments or contingencies as of December 31, 2023 and March 31, 2023. Recently Issued Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standard Board (“FASB”) or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed, the Company does not believe that the impact of recently issued standards that are not yet effective will have a material impact on the Company’s financial position or results of operations upon adoption. There are various other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on our consolidated financial position, results of operations or cash flows. |
Going Concern
Going Concern | 9 Months Ended |
Dec. 31, 2023 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Substantial Doubt about Going Concern [Text Block] | Note 3. Going Concern The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. For the nine months ended December 31, 2023, the Company had a net loss of $23,523. As of December 31, 2023, the Company had a net working capital deficit of $47,755 and an accumulated deficit of $335,676. The Company has begun to recognize revenue, but without additional capital, the Company may not be able to remain in business. The continuation of the Company as a going concern is dependent upon (i) its ability to identify future investment opportunities, (ii) its ability to obtain any necessary debt and/or equity financing, which may include loans from related parties, and (iii) its ability to generate profits from the Company’s future operations. These factors raise a substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the possible inability of the Company to continue as a going concern. Achievement of the Rest EZ, Inc.’s business objective is basically dependent upon the judgment, skill and knowledge of the Company’s management. Mr. Sosa is currently the Company’s sole executive officer and director. There can be no assurance that a suitable replacement could be found for our sole executive officer and director upon his retirement, resignation, inability to act on our behalf, or death. |
Inventory
Inventory | 9 Months Ended |
Dec. 31, 2023 | |
Inventory Disclosure [Abstract] | |
Inventory Disclosure [Text Block] | Note 4. Inventory Inventory consists of one product, a liquid gel capsule named Rest EZ Sleep Aid Supplement, manufactured by an unaffiliated outside provider. At December 31, 2023 and March 31, 2023, inventory consisted of the following: December 31, 2023 March 31, 2023 Finished Goods Inventory $ 2,550 $ 2,550 |
Related Party Transactions
Related Party Transactions | 9 Months Ended |
Dec. 31, 2023 | |
Debt Disclosure [Abstract] | |
Debt Disclosure [Text Block] | Note 5. Related Party Transactions As of March 31, 2023, Brandon Sosa, the Company’s CEO, had loaned the Company the amount of $131,375, for operating capital. During the three and nine months ended December 31, 2023, Mr. Sosa loaned the Company an additional $473 and $17,313, respectively. On December 22, 2023, $140,500 of this amount was converted to 23,000,000 shares of common stock at a price of $0.006 per share. During the three and nine months ended December 31, 2023, the Company charged to operations the amount of $164 and $5,832, respectively, as imputed interest on these loans. During the three and nine months ended December 31, 2022, the Company charged to operations the amount of $2,586 and $7,671, respectively, as imputed interest on these loans. The Company uses a corporate office located at: 1398 W. Mason Hollow Drive, Riverton, Utah 84065. This facility is being provided to the Company free of charge by the Company’s CEO. |
Stockholders' Equity
Stockholders' Equity | 9 Months Ended |
Dec. 31, 2023 | |
Stockholders' Equity Note [Abstract] | |
Equity [Text Block] | Note 6. Stockholders Equity The Company has 100,000,000 authorized shares of common stock with $0.001 par value. On September 26, 2023, the Company’s board of directors approved a reverse stock split in the ratio of 1 for 1000. There were 20,000,000 shares of the Company’s common stock outstanding immediately before the reverse stock split, and 20,000 shares of common stock outstanding immediately after the reverse stock split, a decrease of 19,980,000 shares. The Company issued 33 shares of common stock due to rounding pursuant to the reverse stock split. On December 22, 2023, the Company issued 15,000,000 shares of common stock to its CEO for conversion of a loan. On December 22, 2023, the Company issued 8,000,000 shares of common stock to designees of its CEO for conversion of a loan. As of December 31, 2023 and March 31, 2023, there were 23,020,033 and 20,000 shares of common stock outstanding, respectively. During the three and nine months ended December 31, 2023, the Company charged the amounts of $164 and $5,832, respectively, to additional paid-in capital pursuant to a loan from the Company’s President. During the three and nine months ended December 31, 2022, the Company charged the amounts of $2,586 and $7,671, respectively, to additional paid-in capital pursuant to a loan from the Company’s President. See note 5. |
Income Taxes
Income Taxes | 9 Months Ended |
Dec. 31, 2023 | |
Income Tax Disclosure [Abstract] | |
Income Tax Disclosure [Text Block] | Note 7. Income Taxes There is no current or deferred income tax expense or benefit for the period ended December 31, 2023. The Company has not recognized an income tax expense or benefit for the period based on uncertainties concerning its ability to generate taxable income in future periods. The tax expense for the current period presented is offset by a valuation allowance (100%) established against deferred tax assets arising from operating losses and other temporary differences, the realization of which could not be considered more likely than not. In future periods, tax benefits and related deferred tax assets will be recognized when management considers realization of such amounts to be more likely than not. As of December 31, 2023 and March 31, 2023, the Company has recorded a liability for income taxes payable in the amount of $41,687. The Company is currently analyzing our net operating losses and believes that they will be sufficient to offset all or a significant portion of this liability. |
Subsequent Events
Subsequent Events | 9 Months Ended |
Dec. 31, 2023 | |
Subsequent Events [Abstract] | |
Subsequent Events [Text Block] | Note 8. Subsequent Events On January 14, 2024, the Company entered into two Convertible Note Agreements for an aggregate of $3,200. If not paid within 2 business days, the notes are convertible into common stock at a conversion price of $.002 for an aggregate of 1,867,000. Per the terms of the agreements, the notes were converted into shares of common stock on February 15, 2024. On February 9, 2024, the Company entered into two Convertible Note Agreements for an aggregate of $5,300. If not paid within 1 business day, the notes are convertible into common stock at a conversion price of $.002 for an aggregate of 2,650,000. Per the terms of the agreements, the notes were converted into shares of common stock on February 15, 2024. On January 17, 2024, the Company sold its remaining inventory of 533 bottles of Rest EZ Sleep Aid at $39.99 per bottle, for gross sales of $21,315. The Company has evaluated events occurring subsequent to December 31, 2023 through the date these financial statements were issued and noted no additional items requiring disclosure. |
Accounting Policies, by Policy
Accounting Policies, by Policy (Policies) | 9 Months Ended |
Dec. 31, 2023 | |
Accounting Policies [Abstract] | |
Basis of Accounting, Policy [Policy Text Block] | Basis of Presentation The financial statements have been prepared in accordance with United States generally accepted accounting principles and reflect all adjustments which, in the opinion of management, are necessary for a fair presentation. All such adjustments are of a normal recurring nature. Interim results are not necessarily indicative of results for a full year. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the Company’s financial statements for the year ended March 31, 2023, contained in the Company’s annual report on 10-K/A filed with the SEC on September 13, 2023. On September 26, 2023, the Company’s board of directors approved a reverse stock split in the ration of 1 for 1000. There were 20,000,000 shares of the Company’s common stock outstanding immediately before the reverse stock split, and 20,000 shares of common stock outstanding immediately after the reverse stock split, a decrease of 19,980,000 shares. |
Use of Estimates, Policy [Policy Text Block] | Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, revenue and expenses, and disclosure of contingent liabilities in advance of all conditions being met at the date of the financial statements. Actual results could differ from those estimates. |
Fair Value of Financial Instruments, Policy [Policy Text Block] | Fair Value of Financial Instruments The Company’s balance sheet includes certain financial instruments. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period between the origination of these instruments and their expected realization. FASB Accounting Standards Codification (ASC) 820 Fair Value Measurements and Disclosures Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means. Level 3 - Inputs that are both significant to the fair value measurement and unobservable. The adoption of this standard did not have a material effect on the Company’s financial statements as reflected herein. The carrying amounts of cash and accrued expenses reported on the balance sheet are estimated by management to approximate fair value primarily due to the short-term nature of the instruments. The Company had no items that required fair value measurement on a recurring basis. |
Revenue [Policy Text Block] | Revenue Recognition The Company recognizes revenue from product sales upon product delivery. All of our products are shipped through a third-party fulfillment center to the customer and the customer takes title to product and assumes risk and ownership of the product when it is delivered. Shipping charges to customers and sales taxes collectible from customers, if any, are included in revenues. Deferred revenue recorded on the balance sheet represents payments received by the Company in advance of the product being delivered. We adopted ASC Topic 606, “Revenue from Contracts with Customers”, and all related interpretations for recognition of our revenue. Under ASC 606, the Company recognizes revenue from the commercial sales of products by applying the following steps: (1) identifying the contract with a customer; (2) identifying the performance obligations in the contract; (3) determining the transaction price; (4) allocating the transaction price to each performance obligation in the contract; and (5) recognizing revenue when each performance obligation is satisfied. |
Cash and Cash Equivalents, Policy [Policy Text Block] | Cash and Cash Equivalents All cash is maintained with a major financial institution in the United States. Deposits with this bank may occasionally exceed the amount of insurance provided on such deposits. For the purpose of the financial statements, cash includes cash in banks. Cash was $0 and $44 as of December 31, 2023 and March 31, 2023, respectively. There were no cash equivalents as of December 31, 2023 and March 31, 2023. The Federal Deposit Insurance Corporation (“FDIC”) insures these balances up to $250,000. |
Inventory, Policy [Policy Text Block] | Inventories Inventories are stated at the lower of cost or net realizable value, using the first-in, first-out method. The Company reviews its inventory for obsolescence and any inventory identified as obsolete is reserved or written off. The Company’s determination of obsolescence is based on assumptions about the demand for its products, product expiration dates, estimated future sales, and management’s future plans. |
Income Tax, Policy [Policy Text Block] | Income Taxes The Company accounts for income taxes under ASC 740 Income Taxes |
Commitments and Contingencies, Policy [Policy Text Block] | Commitments and Contingencies The Company follows subtopic 450-20 of the FASB Accounting Standards Codification to report accounting for contingencies. Certain conditions may exist as of the date the financial statements are issued, which may result in a loss to the Company, but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. There are no known commitments or contingencies as of December 31, 2023 and March 31, 2023. |
New Accounting Pronouncements, Policy [Policy Text Block] | Recently Issued Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standard Board (“FASB”) or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed, the Company does not believe that the impact of recently issued standards that are not yet effective will have a material impact on the Company’s financial position or results of operations upon adoption. There are various other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on our consolidated financial position, results of operations or cash flows. |
Inventory (Tables)
Inventory (Tables) | 9 Months Ended |
Dec. 31, 2023 | |
Inventory Disclosure [Abstract] | |
Schedule of Inventory, Current [Table Text Block] | At December 31, 2023 and March 31, 2023, inventory consisted of the following: December 31, 2023 March 31, 2023 Finished Goods Inventory $ 2,550 $ 2,550 |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies (Details) - USD ($) | 9 Months Ended | ||||
Sep. 26, 2023 | Dec. 31, 2023 | Sep. 30, 2023 | Sep. 25, 2023 | Mar. 31, 2023 | |
Accounting Policies [Abstract] | |||||
Stockholders' Equity, Reverse Stock Split | 1 for 1000 | 1 for 1000 | |||
Common Stock, Shares, Outstanding | 20,000 | 23,020,033 | 20,000 | 20,000,000 | 20,000 |
Stock Issued During Period, Shares, Reverse Stock Splits | 19,980,000 | ||||
Cash and Cash Equivalents, at Carrying Value | $ 0 | $ 44 | |||
Cash, FDIC Insured Amount | $ 250,000 |
Going Concern (Details)
Going Concern (Details) - USD ($) | 3 Months Ended | 9 Months Ended | |||
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2023 | Dec. 31, 2022 | Mar. 31, 2023 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |||||
Net Income (Loss) Attributable to Parent | $ (1,184) | $ (4,647) | $ (23,523) | $ (18,850) | |
Working Capital (Deficit) | 47,755 | 47,755 | |||
Retained Earnings (Accumulated Deficit) | $ (335,676) | $ (335,676) | $ (312,153) |
Inventory (Details) - Schedule
Inventory (Details) - Schedule of Inventory, Current - USD ($) | Dec. 31, 2023 | Mar. 31, 2023 |
Schedule Of Inventory Current Abstract | ||
Finished Goods Inventory | $ 2,550 | $ 2,550 |
Related Party Transactions (Det
Related Party Transactions (Details) - USD ($) | 3 Months Ended | 9 Months Ended | ||||
Dec. 22, 2023 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2023 | Dec. 31, 2022 | Mar. 31, 2023 | |
Related Party Transactions (Details) [Line Items] | ||||||
Proceeds from Related Party Debt | $ 473 | $ 17,313 | $ 10,829 | |||
Debt Conversion, Original Debt, Amount | $ 140,500 | 140,500 | 0 | |||
Debt Conversion, Converted Instrument, Shares Issued (in Shares) | 23,000,000 | |||||
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ 0.006 | |||||
Imputed Interest | $ 164 | $ 2,586 | $ 5,832 | $ 7,671 | ||
Chief Executive Officer [Member] | ||||||
Related Party Transactions (Details) [Line Items] | ||||||
Loans Payable | $ 131,375 |
Stockholders' Equity (Details)
Stockholders' Equity (Details) - USD ($) | 3 Months Ended | 9 Months Ended | |||||||
Dec. 22, 2023 | Sep. 26, 2023 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2023 | Dec. 31, 2022 | Sep. 30, 2023 | Sep. 25, 2023 | Mar. 31, 2023 | |
Stockholders' Equity (Details) [Line Items] | |||||||||
Common Stock, Shares Authorized | 100,000,000 | 100,000,000 | 100,000,000 | ||||||
Common Stock, Par or Stated Value Per Share (in Dollars per share) | $ 0.001 | $ 0.001 | $ 0.001 | ||||||
Stockholders' Equity, Reverse Stock Split | 1 for 1000 | 1 for 1000 | |||||||
Common Stock, Shares, Outstanding | 20,000 | 23,020,033 | 23,020,033 | 20,000 | 20,000,000 | 20,000 | |||
Stock Issued During Period, Shares, Reverse Stock Splits | 19,980,000 | ||||||||
Stock Issued During Period, Shares, Stock Splits | 33 | ||||||||
Debt Conversion, Converted Instrument, Shares Issued | 23,000,000 | ||||||||
Imputed Interest (in Dollars) | $ 164 | $ 2,586 | $ 5,832 | $ 7,671 | |||||
Chief Executive Officer [Member] | |||||||||
Stockholders' Equity (Details) [Line Items] | |||||||||
Debt Conversion, Converted Instrument, Shares Issued | 15,000,000 | ||||||||
Investor [Member] | |||||||||
Stockholders' Equity (Details) [Line Items] | |||||||||
Debt Conversion, Converted Instrument, Shares Issued | 8,000,000 |
Income Taxes (Details)
Income Taxes (Details) - USD ($) | Dec. 31, 2023 | Mar. 31, 2023 |
Income Tax Disclosure [Abstract] | ||
Taxes Payable | $ 41,687 | $ 41,687 |
Subsequent Events (Details)
Subsequent Events (Details) - Subsequent Event [Member] | Feb. 15, 2024 shares | Feb. 09, 2024 USD ($) $ / shares | Jan. 17, 2024 USD ($) $ / item | Jan. 14, 2024 USD ($) $ / shares |
Subsequent Events (Details) [Line Items] | ||||
Number of Agreements | 2 | 2 | ||
Debt Instrument, Face Amount | $ | $ 5,300 | $ 3,200 | ||
Debt Instrument, Term | 1 day | 2 days | ||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 0.002 | $ 0.002 | ||
Number of Bottles Sold | 533 | |||
Sales, Price per Bottle | $ / item | 39.99 | |||
Revenue from Contract with Customer, Including Assessed Tax | $ | $ 21,315 | |||
January 14, 2024 Notes [Member] | ||||
Subsequent Events (Details) [Line Items] | ||||
Debt Conversion, Converted Instrument, Shares Issued | shares | 1,867,000 | |||
February 9, 2024 Notes [Member] | ||||
Subsequent Events (Details) [Line Items] | ||||
Debt Conversion, Converted Instrument, Shares Issued | shares | 2,650,000 |